Key points
- A pentapeptide acting as a selective agonist at the ghrelin receptor
- Selectivity is its defining research characteristic, not potency
- Contrasts with earlier GHRPs that show broader endocrine effects
- Mechanistically distinct from GHRH analogues such as CJC-1295 and Tesamorelin
Two routes to the same axis
Growth hormone secretion is regulated through more than one input, and research compounds in this area divide accordingly. GHRH analogues act at the growth hormone-releasing hormone receptor. Secretagogues such as Ipamorelin act at the growth hormone secretagogue receptor, also known as the ghrelin receptor.
These are separate receptors with separate signalling. Compounds acting through them are not variations on a theme, and studies comparing them need to account for that difference rather than treating them as a single category.
What selectivity means here
Ipamorelin is a synthetic pentapeptide, and the property that defines it in the literature is selectivity rather than potency. Earlier growth hormone-releasing peptides — GHRP-6 and GHRP-2 among them — have been reported to produce effects beyond growth hormone release, including on cortisol, prolactin and appetite signalling.
For a researcher, off-target endocrine activity is a confound. If a compound raises several hormones at once, attributing an observed downstream effect to any one of them becomes difficult. A more selective compound produces a cleaner experiment, which is the principal reason Ipamorelin features so heavily in mechanistic work.
Selectivity is relative, not absolute. It is a matter of degree reported across studies, not a guarantee of single-target action.
The pulsatile release problem
Growth hormone is not secreted continuously. It is released in pulses, and the pattern of those pulses appears to carry biological information distinct from total quantity released.
This complicates study design considerably. A single measurement may capture a peak or a trough and give a misleading picture of what a compound is doing. Research in this area typically requires serial sampling, and findings based on isolated measurements should be read with that limitation in mind.
Comparing across the class
GHRP-6 is associated with pronounced appetite-related signalling alongside growth hormone release. GHRP-2 is generally described as more potent for growth hormone release but with retained off-target activity. Ipamorelin is the more selective option with a correspondingly narrower effect profile.
Selecting between them is a question about experimental goals rather than about which is best. A study investigating appetite pathways may specifically want the properties that a mechanistic growth hormone study is trying to exclude.
For laboratory research use only. This article summarises published research for scientific reference. It is not guidance for human or veterinary use, and nothing here describes a treatment for any condition. NexPep compounds are supplied strictly for laboratory research.